Keyphrases
Specific Treatment
100%
Antipsychotics
100%
Tardive Dyskinesia
100%
Risk Ratio
47%
Confidence Interval
35%
Placebo
23%
Chronic Mental Illness
17%
Haloperidol
17%
Risperidone
17%
Antipsychotic Maintenance
17%
People with Schizophrenia
11%
Schizophrenia
11%
Dose Reduction
11%
Second-generation Antipsychotics
11%
Adverse Events
5%
Meta-analysis
5%
Cochrane
5%
Quality of Life Outcomes
5%
Extracted Data
5%
Risk of Bias
5%
Clinical Trials
5%
Adverse Effects
5%
Symptomatic Outcome
5%
Risk Estimation
5%
Small Sample Size
5%
Selection Criteria
5%
Search Methods
5%
Large Trials
5%
Clinically Meaningful Improvement
5%
Movement Disorders
5%
Mental States
5%
Event Outcomes
5%
Social Networks
5%
Group of People
5%
Social Inclusion
5%
Extrapyramidal Symptoms
5%
Quetiapine
5%
Study-based Registers
5%
Involuntary Movement
5%
Social Confidence
5%
Anti-Parkinson
5%
Intermittent Strategy
5%
Intermittent Dosing
5%
Drug Holiday
5%
Cumulative Exposure
5%
Antipsychotic Dose
5%
Dosing Strategy
5%
Medicine and Dentistry
Antipsychotic
100%
Tardive Dyskinesia
100%
Randomized Controlled Trial
46%
Placebo
26%
Chronic Mental Illnesses
20%
Haloperidol
20%
Risperidone
20%
Drug Dose Reduction
13%
Antipsychotic Drug
13%
Quality of Life
6%
Meta-Analysis
6%
Clinical Trial
6%
Adverse Event
6%
Adverse Effect
6%
Mental Health
6%
Stereotypic Movement Disorder
6%
Social Network
6%
Mouth
6%
Quetiapine
6%
Involuntary Movement
6%
Extrapyramidal Symptom
6%
Drug Holiday
6%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Tardive Dyskinesia
100%
Randomized Controlled Trial
46%
Placebo
26%
Diseases
20%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
20%
Risperidone
20%
Antipsychotic Drug
13%
Adverse Event
6%
Clinical Trial
6%
Motor Dysfunction
6%
Quetiapine
6%
Extrapyramidal Symptom
6%
Drug Holiday
6%
Neuroscience
Antipsychotic
100%
Tardive Dyskinesia
100%
Placebo
23%
Haloperidol
17%
Risperidone
17%
Chronic Mental Illnesses
17%
Meta-Analysis
5%
Face
5%
Quality of Life
5%
Adverse Effect
5%
Stereotypic Movement Disorder
5%
Extrapyramidal Symptom
5%
Quetiapine
5%
Psychology
Tardive Dyskinesia
100%
Schizophrenia
36%
Mental Illness
27%
Haloperidol
27%
Meta-Analysis
9%
Quality of Life
9%
Mental State
9%
Main Result
9%
Movement Disorder
9%